207 related articles for article (PubMed ID: 28079291)
1. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Kim HM; Lee J; Koo JS
BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J
Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405
[TBL] [Abstract][Full Text] [Related]
7. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Monneur A; Gonçalves A; Bertucci F
Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
[TBL] [Abstract][Full Text] [Related]
8. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T
PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453
[TBL] [Abstract][Full Text] [Related]
10. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Li S; Chen L; Jiang J
Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Yang L; Xue R; Pan C
Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
[No Abstract] [Full Text] [Related]
13. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W; Ran R; Shao B; Li H
Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
Zhao T; Li C; Wu Y; Li B; Zhang B
PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
Liu X; Shan C; Song Y; Du J
Front Oncol; 2019; 9():1111. PubMed ID: 31709181
[No Abstract] [Full Text] [Related]
17. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850
[TBL] [Abstract][Full Text] [Related]
19. Predictive values of PD‑L1 expression for survival outcomes in patients with cervical cancer: a systematic review and meta-analysis.
Hu T; Wan X; Wu H; Cheng X; Xu S
Ginekol Pol; 2022; 93(10):767-774. PubMed ID: 35984342
[TBL] [Abstract][Full Text] [Related]
20. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
